Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
May 3, 2023

ODAIA raises $25 Million

Company to expand its AI-powered solutions that help s develop treatments

ODAIA, a Canadian startup that specializes in developing MAPTUAL, an AI-powered commercial insights SaaS platform for pharmaceutical companies, has successfully raised $25 million in Series B funding. The funding round was co-led by Threshold Ventures and Monograph Capital, with participation from Wittington Ventures and existing investors Flint Capital, BDC Capital’s Women in Technology Venture Fund, StandUp Ventures, and Graphite Ventures.

Through this funding, ODAIA hopes to expand its business and support the growth of its AI-powered solutions, as the company's mission is to help pharmaceutical companies make life-changing therapies more accessible to patients. It is important to Philip Poulidis, CEO and Co-Founder of ODAIA, that investors recognize the significant problem the company solves for the pharmaceutical industry. In order to provide its clients with the predictive tools they need for today's and tomorrow's market, ODAIA is continuing to enhance its product and build its team with these funds.

ODAIA's lead product, MAPTUAL, is a SaaS platform that uses AI to automate the prospecting, qualifying, and engagement of healthcare providers (HCP), which has traditionally been a manual and time-consuming process. MAPTUAL empowers leading life science brands by providing a near real-time and predictive perspective on the dynamic changes of the pharmaceutical marketplace, enabling more efficient delivery of therapeutics, drugs, and vaccines to the markets that need them.

As part of the funding round, Emily Melton, managing partner of Threshold Ventures, and Charles Conn, co-founder and partner of Monograph Ventures, will join ODAIA's board, and Megan Kelly, principal of Threshold Ventures, will join as a board observer. This funding will allow ODAIA to continue revolutionizing pharmaceutical marketing and commercialization with its AI-powered solutions, ultimately helping patients receive life-changing therapies faster.

Neil Hodgson Coyle
Neil Hodgson-Coyle
Editorial chief at TechNews180
Back to top

Related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram